Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001387131-21-002579
Filing Date
2021-02-17
Accepted
2021-02-17 08:26:24
Documents
2
Group Members
ATLAS VENTURE ASSOCIATES OPPORTUNITY I, L.P.ATLAS VENTURE ASSOCIATES OPPORTUNITY I, LLCATLAS VENTURE ASSOCIATES X, L.P.ATLAS VENTURE ASSOCIATES X, LLCATLAS VENTURE OPPORTUNITY FUND I, L.P.

Document Format Files

Seq Description Document Type Size
1 AMENDED ACQUISITION OF BENEFICIAL OWNERSHIP magenta-sc13da_021121.htm SC 13D/A 132157
2 JOINT FILING AGREEMENT ex-b.htm EX-99.B 20044
  Complete submission text file 0001387131-21-002579.txt   154012
Mailing Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139
Business Address 400 TECHNOLOGY SQUARE 10TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Atlas Venture Fund X, L.P. (Filed by) CIK: 0001628098 (see all company filings)

IRS No.: 472435989 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A

Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Subject) CIK: 0001690585 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-90538 | Film No.: 21642720
SIC: 2834 Pharmaceutical Preparations